home / stock / avxl / avxl quote
Last: | $6.835 |
---|---|
Change Percent: | -2.87% |
Open: | $6.81 |
Close: | $6.835 |
High: | $7.07 |
Low: | $6.5 |
Volume: | 2,000,018 |
Last Trade Date Time: | 11/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$6.835 | $6.81 | $6.835 | $7.07 | $6.5 | 2,000,018 | 11-01-2024 |
$6.62 | $5.88 | $6.62 | $7.37 | $5.87 | 5,850,692 | 10-31-2024 |
$5.71 | $5.66 | $5.71 | $5.8491 | $5.6214 | 313,475 | 10-30-2024 |
$5.715 | $5.74 | $5.715 | $5.83 | $5.64 | 504,813 | 10-29-2024 |
$5.78 | $5.29 | $5.78 | $5.79 | $5.29 | 699,838 | 10-28-2024 |
$5.24 | $5.38 | $5.24 | $5.57 | $5.22 | 615,077 | 10-25-2024 |
$5.33 | $5.4 | $5.33 | $5.46 | $5.3 | 443,363 | 10-24-2024 |
$5.39 | $5.59 | $5.39 | $5.7008 | $5.31 | 701,584 | 10-23-2024 |
$5.64 | $5.4 | $5.64 | $5.68 | $5.285 | 645,429 | 10-22-2024 |
$5.45 | $5.63 | $5.45 | $5.77 | $5.395 | 758,617 | 10-21-2024 |
$5.65 | $5.52 | $5.65 | $5.7 | $5.46 | 440,193 | 10-18-2024 |
$5.505 | $5.65 | $5.505 | $5.65 | $5.43 | 467,283 | 10-17-2024 |
$5.525 | $5.4 | $5.525 | $5.6 | $5.39 | 536,367 | 10-16-2024 |
$5.39 | $5.41 | $5.39 | $5.51 | $5.3216 | 380,316 | 10-15-2024 |
$5.41 | $5.36 | $5.41 | $5.555 | $5.33 | 488,967 | 10-14-2024 |
$5.38 | $5.11 | $5.38 | $5.4 | $5.11 | 498,325 | 10-11-2024 |
$5.11 | $5.06 | $5.11 | $5.14 | $5.03 | 406,858 | 10-10-2024 |
$5.13 | $5.21 | $5.13 | $5.3 | $5.1 | 600,826 | 10-09-2024 |
$5.24 | $5.34 | $5.24 | $5.54 | $5.2099 | 620,506 | 10-08-2024 |
$5.37 | $5.6 | $5.37 | $5.6 | $5.36 | 345,165 | 10-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed clinical decline for early Alzheimer's disease patients...
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX ® 3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are currently being dosed in Part B of the Phase 2 study which will investigate a l...
2024-10-16 11:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...